Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

Latest Articles

  • You have access
    From bathtub ring to osteoporosis: a clinical review of the bisphosphonates
    Angelo A. Licata, MD, PhD
    Cleveland Clinic Journal of Medicine July 1993, 60 (4) 284-290;

    BACKGROUND Etidronate and pamidronate are bisphosphonates, a class of chemical compounds originally used to soften hard water and prevent soap scum. Etidronate was serendipitously found to abate calcification in a child with myositis ossificans progressiva.

    OBJECTIVE Review the basic pharmacology of these compounds, as well as clinical uses of the approved and nonapproved forms.

    DISCUSSION Etidronate is approved for the treatment of hypercalcemia, Paget’s disease of bone, and ectopic calcification, and has been used to treat hyperparathyroidism and nephrolithiasis with limited success. Recently it has been used to treat osteoporosis. Pamidronate is approved to treat hypercalcemia. These two drugs are the only bisphosphonates available in the United States.

    CONCLUSIONS Clinical trials with etidronate have aroused widespread interest in the application of bisphosphonates to treat osteoporosis. Many trials are underway to evaluate these new drugs. More information will be available within the next 5 years.

  • You have access
    Lung transplantation: the Cleveland Clinic experience
    Sunit R. Patel, MD, Thomas J. Kirby, MD, Patrick M. McCarthy, MD, David P. Meeker, MD, Paul Stillwell, MD, Thomas W. Rice, MD, Mani S. Kavuru, MD and Atul C. Mehta, MD
    Cleveland Clinic Journal of Medicine July 1993, 60 (4) 303-319;

    BACKGROUND Lung transplantation has been steadily developing as a therapeutic option for end-stage lung disease.

    METHODS Retrospective analysis of all 26 patients who underwent lung transplantation at the Cleveland Clinic Foundation between February 1990 and February 1992.

    RESULTS Nineteen single-lung transplantations and seven bilateral lung transplantations were performed. The 1-year actuarial survival for all recipients was 65%. A trend was noted towards better survival in recipients with emphysema (100%) and poorer survival in those with pulmonary hypertension (37.5%). Fungal sepsis and reimplantation lung injury were the most common causes of death, and most deaths (8 of 9) occurred within the first 4 weeks. Of 119 pulmonary complications, 82% occurred in the first 3 months, with infection (39%) and acute rejection (29%) being the most common. Bacterial and fungal infections occurred mainly in the first month, and cytomegalovirus infections occurred mainly in the second and third months. The majority of survivors have shown improvement in functional status.

    CONCLUSIONS The early perioperative and 1-month post-transplantation period appears critical to long-term survival. Even though the complications are numerous, they are usually manageable and, in general, do not result in long-term morbidity.

  • You have access
    Parkinson’s disease: where do westand?
    Patrick J. Sweeney, MD
    Cleveland Clinic Journal of Medicine July 1993, 60 (4) 269-270;

    Although a cure has not been found, certain drugs can relieve symptoms and may actually slow disease progression.

  • You have access
    The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: insights and highlights from the chairman
    Alan Bakst, PharmD and Ray W. Gifford, MD
    Cleveland Clinic Journal of Medicine July 1993, 60 (4) 273-277;

    Highlights include the new classification schema and recommendations on the use of labetalol.

  • You have access
    Hemopericardium and cardiac tamponade associated with warfarin therapy
    Kamthorn S. Lee, MD and Thomas Marwick, MD
    Cleveland Clinic Journal of Medicine July 1993, 60 (4) 336-338;
  • You have access
    Discussion
    David L. Longworth, MD
    Cleveland Clinic Journal of Medicine May 1993, 60 (3) 188;
  • You have access
    The role of multiple risk factors in cardiovascular morbidity and mortality
    Ray W. Gifford, MD
    Cleveland Clinic Journal of Medicine May 1993, 60 (3) 211-218;

    BACKGROUND Cardiovascular disease remains the leading cause of death in the United States.

    OBJECTIVE To identify important modifiable cardiovascular risk factors and appropriate interventions.

    DISCUSSION The three most important modifiable risk factors are hypertension, cigarette smoking, and dyslipidemia. Systolic hypertension poses a greater risk than diastolic, but the prognostic significance of diastolic blood pressure may have been underestimated. When a smoker quits, the cardiovascular risk soon approaches that of the nonsmoker. Cardiovascular risk increases progressively with elevations of the serum total cholesterol level above 200 mg/dL. Recently identified risk factors include hyperinsulinemia and left ventricular hypertrophy.

    CONCLUSION Each patient deserves an evaluation of cardiovascular risk followed by education about and therapy for those risk factors that can be changed. When more than one risk factor is present, as is often the case, the increase in risk may be synergistic rather than additive.

  • You have access
    Theophylline in the ambulatory treatment of chronic obstructive lung disease: resolving a controversy
    Gordon L. Snider, MD
    Cleveland Clinic Journal of Medicine May 1993, 60 (3) 197-201;

    BACKGROUND Recent reports of a high frequency of theophylline toxicity, which usually occurs at theophylline blood levels >20 μg/mL, coupled with the recent addition of metered-dose, inhaled anticholinergics to the beta-2 agonist inhalers already available for treatment of chronic obstructive pulmonary disease, has led some authors to suggest that theophylline should no longer be used in the ambulatory management of this disease.

    OBJECTIVE The author suggests an alternate approach to theophylline dosing as a means of resolving the current controversy.

    SUMMARY Because of the log-linear relationship between bronchodilation and blood level, little bronchodilator efficacy is lost by using a target therapeutic theophylline blood level of 10 ± 2 μg/mL. This target provides a greater range between therapeutic and toxic blood levels than the 17 ± 2 μg/mL therapeutic target blood level that has also been recommended.

    CONCLUSIONS Because theophylline has a different mode of action than the sympathomimetic or anticholinergic drugs, it continues to have a useful place in the ambulatory management of chronic obstructive pulmonary disease.

  • You have access
    Hemodialysis-induced hypotension: the search for a cause
    Fetnat M. Fouad, MD
    Cleveland Clinic Journal of Medicine May 1993, 60 (3) 192-193;
  • You have access
    A medical approach to nicotine addiction treatment
    Thomas L. Petty, MD and Louise M. Nett, RN, RRT
    Cleveland Clinic Journal of Medicine May 1993, 60 (3) 254-258;

Pages

  • Previous
  • Next
  • 1
  • …
  • 483
  • 484
  • 485
  • 486
  • 487
  • 488
  • 489
  • 490
  • 491
  • …
  • 799

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire